NZ Hepatitis Research Review Issue 35

In this issue:

  • Serological response to HBV revaccination
  • Entecavir vs tenofovir for treatment-naive chronic HBV
  • HEV in patients with haematological malignancies
  • Direct-acting antivirals in chronic HCV with HCC
  • REAL-B risk score for prediction of HCC in chronic HBV
  • Glecaprevir/pibrentasvir for chronic HCV and compensated cirrhosis
  • Safety of direct-acting antiviral agents for hepatitis C
  • Simplified hepatitis C virus monitoring with glecaprevir plus pibrentasvir
  • Short duration glecaprevirpibrentasvir for recent HCV
  • Patient-reported outcomes with direct-acting antiviral therapies for chronic HCV

Please login below to download this issue (PDF)